Megan Hollasch

Articles

Adjuvant Nivolumab Displays Real-world Benefits in Resected Stage IIIA Melanoma

November 27th 2022

Adjuvant nivolumab produced survival benefits in patients with resected stage IIIA melanoma, where a significant portion of patients were recurrence free at a median follow-up of over 20 months.

Updates from Melanoma Trials Demonstrate New Roles for Adjuvant/Neoadjuvant Treatment

November 23rd 2022

Sapna Patel, MD, reviews several key studies across stages of melanoma and emerging targeted therapies for patients with BRAF mutations.

Advances in Breast Cancer Treatment Reshape Treatment Paradigms in 2022

November 21st 2022

The increasing role of antibody-drug conjugates have led to questions of sequencing for patients with HER2-positive breast cancer, whereas new data for first-generation PD-L1 inhibitors, such as pembrolizumab have shaken up the treatment paradigm for others.

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21st 2022

Molecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods are taken up in clinical practice.

Clinical Trials Propel New Standards of Care for Thyroid Cancer

November 12th 2022

Alan L. Ho, MD, PhD, discusses targeted therapies such as TKIs that have demonstrated promising efficacy in multiple patient populations as well as the agents lenvatinib and pembrolizumab.

Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer

November 11th 2022

As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.

Role of PSMA-PET Expands in the Treatment of Prostate Cancer

November 11th 2022

David Albala, MD, discusses integrating PSMA-PET imaging into the clinic and determining which patients with prostate cancer are prime candidates.

Shore Unpacks Treatment Advances for Patients With Urologic Cancers

November 11th 2022

Neal Shore, MD, FACS, highlights the effect of genetic testing on the treatment paradigm of prostate cancer and the evolving treatment landscape for metastatic castration resistant prostate cancer.

Sequencing Strategies, Improving QOL Are Top Priorities in Neuroendocrine Neoplasm Treatment

November 10th 2022

Diane Reidy-Lagunes, MD, discussed the role of next-generation sequencing paired with systemic therapies and the option of peptide receptor radionuclide therapy in neuroendocrine malignancies.

Petrylak Previews Shift in Sequencing Paradigm in Urothelial Cancer

November 9th 2022

Daniel P. Petrylak, MD, highlights the use of checkpoint inhibitors, antibody-drug conjugates, and FGFR inhibitors in urothelial cancer and the current sequencing hurdles in the paradigm.

Adagrasib With Cetuximab Moves Into Phase 3 for KRAS G12C–Mutated CRC

November 3rd 2022

Rona Yaeger, MD, discusses the unmet needs for patients with KRAS G12C–mutated colorectal cancer and the promising combination therapy of adagrasib and cetuximab.

Futibatinib Approval Expands Options for Patients With FGFR2+ Cholangiocarcinoma

October 19th 2022

The accelerated approval of the FGFR inhibitor futibatinib on September 30, 2022, has expanded options for previously treated adult patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma FGFR2 fusions or rearrangements.1

Treatments for MCL Continue to Progress

October 14th 2022

As research and treatment options for patients with mantle cell lymphoma continue to expand, the development of risk-adapted therapies for the 3 primary subtypes—blastoid, smoldering, and classic broad-spectrum—represents a crucial next step in the field.

Abemaciclib Dose Reductions Lead to Prolonged Treatment in HR+/HER2- Breast Cancer

October 13th 2022

Abemaciclib produced a clinically manageable safety profile in patients with hormone receptor–positive, HER2-negative, early breast cancer or advanced breast cancer, and dose reductions were found to effectively mitigate discontinuation.

Sonpavde Reviews Urothelial Carcinoma Treatment Highlights from ESMO 2022

October 6th 2022

Guru P. Sonpavde, MD, provides commentary on several studies in urothelial carcinoma and how data presented at ESMO may affect clinical practice.

Derazantinib Demonstrates Promising Efficacy in Intrahepatic Cholangiocarcinoma

October 5th 2022

Patients with locally advanced or metastatic intrahepatic cholangiocarcinoma who received the FGFR inhibitor derazantinib derived a meaningful clinical benefit with a manageable safety profile.

Multicenter Review Supports TKI Use in Patients With mRCC and Bone Metastases

September 20th 2022

An analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.

HRQOL Is Maintained With Nivolumab in Real-World Population of Pretreated mRCC

September 20th 2022

Health-related quality of life was maintained following treatment with nivolumab in the second- or third-line settings in patients with previously treated metastatic renal cell carcinoma, according to findings from a real-world retrospective analysis.

Atezolizumab and Bevacizumab TRAEs are Potential Predictors of Favorable Outcomes in HCC

September 16th 2022

Patients with hepatocellular carcinoma who developed treatment-related adverse effects associated with atezolizumab plus bevacizumab had improved overall survival and progression-free survival outcomes.

Changes Improve Radiation Therapy in SCLC

September 16th 2022

Investigators are making progress in delineating the optimal use of radiation therapy for the treatment of patients with small cell lung cancer, which remains a cornerstone of therapy for the malignancy, particularly in limited-stage disease.